Abbott Laboratories

ABT

New York Stock Exchange. Currency in USD

107.93 +0.35 ( +0.33% )

Real time prices: December 01

Market Cap.
188.18B
Beta (5Y monthly)
0.69
Price/Earnings
18.83
EPS (TTM)
5.63
Forward Dividend
1.88 (1.75%)
Ex-Dividend Date
Oct 14, 2022
Volume
5.08M
1y Target Est.
116.38
Day's Range
107.35
-
108.65
52 Week's Range
93.25
-
142.60

Historical Summary

Performance
EPS growth
Share Buybacks

About Abbott Laboratories

Sector
Healthcare
Industry
Medical Devices
Website
https://www.abbott.com
Exchange
New York Stock Exchange (XNYS)
Shares Outstanding
1.77B
Employees
113000
Address
100 Abbott Park Road, North Chicago, IL, United States, 60064-6400
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Latest news

Abbott (ABT) Gains As Market Dips: What You Should Know
Abbott (ABT) Gains As Market Dips: What You Should Know

Abbott (ABT) closed at $107.93 in the latest trading session, marking a +0.33% move from...
By Zacks Investment Research - 11 hours ago

S&P 500's Best Dividend Aristocrats
S&P 500's Best Dividend Aristocrats

Investors looking for stability and payout growth should look closer at Dividend Aristocrat stocks.
By The Motley Fool - 1 day ago

3 Top Dividend Kings to Buy for the Long Haul
3 Top Dividend Kings to Buy for the Long Haul

Dividend stocks are an easy option to boost income.
By The Motley Fool - 1 day ago

Is Trending Stock Abbott Laboratories (ABT) a Buy Now?
Is Trending Stock Abbott Laboratories (ABT) a Buy Now?

Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth...
By Zacks Investment Research - 3 days ago

8 Dividend Aristocrats to Buy Now for a Lifetime of Passive Income
8 Dividend Aristocrats to Buy Now for a Lifetime of Passive Income

Dividend stocks are a great way to protect against a downturn and these are the...
By The Motley Fool - 4 days ago

Is This Stock-Split Stock a Buy For 2023?
Is This Stock-Split Stock a Buy For 2023?

Don't buy this company's shares for its recent stock split.
By The Motley Fool - 5 days ago

Better Dividend Stock: AbbVie or Viatris?
Better Dividend Stock: AbbVie or Viatris?

These pharmaceutical companies are profitable and offer above-average dividends.
By The Motley Fool - 5 days ago